Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 8/20 | 0.86 |
| ▸ | ERBB2 | P04626 | 11/20 | 0.48 |
| ▸ | EGFR | P00533 | 6/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16788366 | 1.00 | BTK (0.86) | BTKERBB2EGFR | |
| SCHEMBL16440887 | 0.97 | BTK (0.80) | BTKERBB2EGFR | |
| SCHEMBL166896 | 0.93 | BTK (1.00) | BTKERBB2EGFR | |
| SCHEMBL19993798 | 0.93 | BTK (1.00) | BTKERBB2EGFR | |
| SCHEMBL19728633 | 0.84 | BTK (0.62) | BTKERBB2EGFR | |
| SCHEMBL122280 | 0.84 | BTK (1.00) | BTKEGFR | |
| SCHEMBL18905245 | 0.84 | BTK (0.61) | BTKERBB2EGFR | |
| SCHEMBL169757 | 0.84 | BTK (0.85) | BTKERBB2EGFR | |
| SCHEMBL124181 | 0.83 | BTK (0.82) | BTKERBB2EGFR | |
| SCHEMBL174843 | 0.82 | BTK (0.80) | BTKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180078555-A1 | METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE | PHARMACYCLICS, INC. | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180078555-A1 | METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE | BLK, DCK, CILK1 | BTK 8/4885ERBB2 1467/4885EGFR 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.